The Latest Cancer Immunotherapy Industry Statistics Explained
A new market research report states that the Cancer Immunotherapy Market is expected to reach USD 119.39 Billion by 2021.
The statistic about the Cancer Immunotherapy Market reaching USD 119.39 Billion by 2021 indicates a significant financial outlook for this particular sector. This figure suggests a strong and growing demand for cancer immunotherapy treatments worldwide, reflecting positive trends in research, development, and adoption of such therapies. The projected market value serves as an indicator of the potential for substantial revenue generation and investment opportunities in the cancer immunotherapy market, highlighting the increasing significance of this innovative approach in the fight against cancer.
North America dominated the global cancer immunotherapy market in 2019, accounting for a 34.9% share.
The statistic “North America dominated the global cancer immunotherapy market in 2019, accounting for a 34.9% share” indicates that the region of North America held the largest portion of the global market for cancer immunotherapy during that year. With a share of 34.9%, North America surpassed other regions in terms of the value of cancer immunotherapy products and services consumed or produced. This dominance suggests that North America was a key player in the advancement and adoption of cancer immunotherapy treatments, potentially driven by factors such as technological innovation, supportive regulatory environment, and significant investments in research and development within the region.
Europe occupied a market share of 31.8% of the global cancer immunotherapy market in the very same year.
This statistic indicates that in the specified year, Europe accounted for 31.8% of the total market share in the global cancer immunotherapy market. This suggests that European countries collectively held a significant portion of the market relative to other regions or countries worldwide. The market share figure of 31.8% highlights the prominence of Europe in the field of cancer immunotherapy and underscores its importance as a major player in this particular sector of the healthcare industry.
The lung cancer segment is expected to grow at the highest CAGR of over 20% from 2016 to 2024.
This statistic suggests that the market for lung cancer-related products and services is forecasted to experience the highest Compound Annual Growth Rate (CAGR) among all other segments from 2016 to 2024. A CAGR of over 20% implies a substantial and rapid expansion in the market size, indicating increasing demand and investment in lung cancer detection, treatment, research, and related areas. This projection highlights the significance of addressing lung cancer as a key area for growth and innovation within the healthcare industry over the specified timeframe.
In 2020, among different cancer types, breast cancer held the largest market share and is predicted to maintain its dominance during the forecast period.
In 2020, breast cancer was reported to have the highest prevalence among different types of cancers, indicating that it held the largest market share in terms of diagnosed cases and possibly treatment expenditures within the healthcare market. The prediction that breast cancer will continue to maintain its dominance during the forecast period suggests that it is expected to remain the most commonly diagnosed and treated cancer type in the coming years. This statistic highlights the significant impact of breast cancer on healthcare resources and underscores the ongoing need for research, resources, and interventions to address this prevalent and burdensome disease.
Global Cancer Immunotherapy Market is expected to grow at a growth rate of 14.76% from 2020 to 2027.
This statistic indicates that the global market for cancer immunotherapy is projected to experience a substantial growth rate of 14.76% between the years 2020 and 2027. This growth rate signifies the anticipated increase in market size and demand for cancer immunotherapy products and services over the specified time period. Factors driving this growth may include advancements in immunotherapy research and development, increased awareness and adoption of immunotherapy treatments, and a rising burden of cancer worldwide. This statistic suggests promising opportunities for the cancer immunotherapy market in the coming years, with a potential for significant expansion and innovation in the field.
Immune Checkpoint Inhibitors held the largest revenue share and was valued at USD 20.3 Billion in 2015.
This statistic indicates that in 2015, Immune Checkpoint Inhibitors, a type of cancer treatment medication, had the highest revenue share among all pharmaceutical products, valued at USD 20.3 billion. This suggests that Immune Checkpoint Inhibitors were in high demand and generated significant sales revenue compared to other drugs within the same market. This information is important for pharmaceutical companies, investors, and healthcare professionals as it highlights the market dominance and commercial success of Immune Checkpoint Inhibitors, reflecting their perceived effectiveness and adoption in the medical community for treating cancer.
At a regional level, the Asia-Pacific market will be growing at a CAGR of 14.3% over 2020-2027.
This statistic indicates that the Asia-Pacific market is projected to experience significant growth over the period from 2020 to 2027 with a Compound Annual Growth Rate (CAGR) of 14.3%. This implies that on average, the market size in the Asia-Pacific region is expected to increase by 14.3% year-over-year during this time frame. The CAGR serves as a useful measure for evaluating the steady annual growth rate of the market and highlights the potential business opportunities and economic expansion in the Asia-Pacific region. This growth rate suggests a thriving market environment with increasing demand, investment opportunities, and overall economic prosperity within the region.
From 2015 to 2023, lung cancer is predicted to expand its market size to15.5%.
The statistic “From 2015 to 2023, lung cancer is predicted to expand its market size to 15.5%” indicates that the market size of lung cancer, in terms of prevalence, incidence, or economic impact, is projected to increase by 15.5% over the mentioned time period. This suggests a substantial growth in the impact of lung cancer on the healthcare system, society, and the economy. Such an expansion could be driven by various factors such as changes in risk factors, advancements in detection and treatment methods, shifting demographics, or other influences. This statistic underscores the importance of addressing lung cancer as a significant public health concern and highlights the need for proactive strategies to mitigate its impact.
Cell therapies segment is anticipated to exhibit the highest CAGR, around 15.8% over the coming years.
The statistic indicates that the cell therapies segment is expected to experience the highest Compound Annual Growth Rate (CAGR) compared to other segments in the upcoming years. A CAGR of 15.8% suggests a substantial and consistent growth rate for cell therapies, reflecting positive market trends and potential opportunities in this sector. This high CAGR may be driven by factors such as advancements in regenerative medicine, increasing research and development activities, growing acceptance of cell-based treatments, and expanding applications across various medical fields. The outlook for the cell therapies market appears promising, with the potential for significant growth and innovation in the near future.
The Cancer Immunotherapy market accounted for $58,145.34 million in 2019 and is expected to reach $182,709.61 million by 2027 growing at a CAGR of 15.3% during the forecast period.
The statistic provided indicates that the Cancer Immunotherapy market experienced a significant value of $58,145.34 million in 2019 and is projected to grow substantially to $182,709.61 million by 2027, representing a Compound Annual Growth Rate (CAGR) of 15.3% over the forecast period. This implies a rapid and substantial increase in market size for Cancer Immunotherapy, reflecting growing demand and adoption of immunotherapy treatments for cancer. The high CAGR suggests a strong market potential and opportunities for stakeholders in the cancer immunotherapy industry, with the market expected to expand at a notable rate in the coming years, driven by advancements in treatment technologies and increasing awareness of the benefits of immunotherapy in cancer management.
The cancer vaccines accounted for the highest growth rate among the cancer immunomodulators, with an estimated CAGR of over 15% from 2016 to 2024.
The statistic indicates that within the cancer immunomodulators market, cancer vaccines experienced the most significant growth rate over the period from 2016 to 2024, with a compounded annual growth rate (CAGR) exceeding 15%. This suggests that there was a substantial increase in the demand, adoption, and development of cancer vaccines during this timeframe, highlighting a strong positive trend in the utilization of vaccines as an immunomodulatory treatment for cancer. The high growth rate for cancer vaccines implies a promising outlook for advancements in this specific area of cancer treatment, potentially leading to improvements in patient outcomes and advancements in the field of oncology.
The top three companies involved in the development of immune checkpoint inhibitors held over 60% share of this segment in 2018.
This statistic indicates that in 2018, the top three companies leading the development of immune checkpoint inhibitors collectively accounted for over 60% of the market share within this segment. This suggests a high level of concentration and dominance by these companies in advancing research and innovation in immune checkpoint inhibitors. The market share held by these top companies highlights their significant influence and competitive advantage in shaping the development and commercialization of immune checkpoint inhibitors, potentially impacting the treatment landscape and healthcare outcomes in the field of immunotherapy.
Checkpoint inhibitors are expected to reach over USD 56.5 billion in 2025, experiencing growth at a CAGR of 19% from 2017 to 2025.
The statistic indicates that the market value of checkpoint inhibitors, a type of immunotherapy used in cancer treatment, is forecasted to exceed USD 56.5 billion by the year 2025. This projection signifies a substantial increase from the base year of 2017, with a compound annual growth rate (CAGR) of 19% being anticipated over the period from 2017 to 2025. The high CAGR suggests a strong and consistent growth trajectory for the checkpoint inhibitors market, driven by factors such as ongoing research and development efforts, increasing adoption of immunotherapies in cancer treatment, and a growing number of approved indications for these therapies.
In 2018, global cancer immunotherapy market pharmaceuticals spending increased by 6.5% to touch $1.2 trillion.
The statistic indicates that the global spending on cancer immunotherapy pharmaceuticals in 2018 rose by 6.5% compared to the previous year, reaching a total of $1.2 trillion. This substantial increase reflects the growing importance and investment in cancer immunotherapy treatments, which harness the body’s immune system to fight cancer cells. The rise in spending suggests a significant shift towards immunotherapy as a key approach in cancer treatment and underscores the continuous advancements and innovations in this field. The significant monetary investment highlights the increasing prioritization of developing and providing cancer patients with effective immunotherapy options on a global scale.
Global Cancer Immunotherapy Market from Cancer Vaccines is expected to grow at the highest CAGR of around 15% from 2021 to 2027.
This statistic indicates the projected growth rate of the global cancer immunotherapy market specifically from cancer vaccines, with a compound annual growth rate (CAGR) of approximately 15% expected from 2021 to 2027. This signifies a significant increase in market size and demand for cancer vaccines as a form of immunotherapy to treat cancer patients worldwide. The high growth rate suggests a strong market potential for cancer vaccines, driven by factors such as advancements in technology, increasing prevalence of cancer cases, growing awareness about immunotherapy, and the potential benefits of vaccines in enhancing immune responses against cancer cells. Overall, this statistic highlights the positive outlook for the cancer immunotherapy market, particularly in the segment focused on cancer vaccines, over the specified period.
References
0. – https://www.www.marketresearchfuture.com
1. – https://www.pharmaceuticalcommerce.com
2. – https://www.markets.businessinsider.com
3. – https://www.www.gminsights.com
4. – https://www.www.globenewswire.com
5. – https://www.www.rootsanalysis.com
6. – https://www.www.databridgemarketresearch.com
7. – https://www.www.transparencymarketresearch.com
8. – https://www.www.grandviewresearch.com
9. – https://www.www.prnewswire.com
10. – https://www.www.fortunebusinessinsights.com
